IPIAD: An Augmentation to Standard Treatment of PDAC Using Five Repurposed Drugs
February 9, 2024
PRESS RELEASE: On February 7, 2024, a new research perspective was published in Oncoscience, entitled, “IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.” continue reading »